{"id":"ustekinumab-ust","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":{"setId":"853130e5-7406-4fd6-8138-ff2179195927","title":"OTULFI (USTEKINUMAB-AAUZ) INJECTION, SOLUTION OTULFI (USTEKINUMAB-AAUZ) SOLUTION [FRESENIUS KABI USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ustekinumab inhibits interleukin-12 (IL-12) and interleukin-23 (IL-23), which are key cytokines involved in T-cell differentiation and inflammatory responses. By blocking the p40 subunit common to both cytokines, it suppresses Th1 and Th17 cell-mediated inflammation, making it effective in immune-mediated inflammatory diseases. This mechanism is particularly useful in conditions driven by dysregulated T-cell responses.","oneSentence":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 signaling pathways by binding to their shared p40 subunit, reducing inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:24.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300},{"nctId":"NCT07303686","phase":"PHASE4","title":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-08","conditions":"Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":115},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide, Ustekinumab","enrollment":818},{"nctId":"NCT07057856","phase":"","title":"An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Crohn's Disease","enrollment":866},{"nctId":"NCT06997055","phase":"","title":"ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar","status":"RECRUITING","sponsor":"Celltrion HealthCare France","startDate":"2025-03-17","conditions":"Crohn Disease, Plaque Psoriasis","enrollment":225},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":906},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":839},{"nctId":"NCT06912815","phase":"NA","title":"Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.","status":"RECRUITING","sponsor":"Xiang Gao","startDate":"2024-08-01","conditions":"Crohn Disease (CD)","enrollment":184},{"nctId":"NCT06849739","phase":"","title":"Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-03-02","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT06785493","phase":"","title":"The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-07-01","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":122},{"nctId":"NCT05861167","phase":"PHASE4","title":"SIIT Based on UST CDST in Patients With CD","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-06-01","conditions":"Crohn Disease","enrollment":140},{"nctId":"NCT05705856","phase":"","title":"Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-02-15","conditions":"Crohn Disease","enrollment":200},{"nctId":"NCT05386290","phase":"","title":"A Multicentered Prospective Cohort Study of Chinese IBD Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-09","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":200},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stelara"],"phase":"marketed","status":"active","brandName":"Ustekinumab (UST)","genericName":"Ustekinumab (UST)","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 signaling pathways by binding to their shared p40 subunit, reducing inflammatory immune responses. Used for Plaque psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}